Diverse group of women with bronchiectasis (BE) image

It’s possible to have fewer bronchiectasis flares

In a 1-year clinical study, BRINSUPRI:

Reduced the risk of bronchiectasis (BE) flares

Helped more patients remain flare-free for a year

Reduced the decline of lung function with the 25-mg dose

Scroll to learn more

BRINSUPRI was studied in the largest bronchiectasis clinical trial program

BRINSUPRI was approved based on 2 clinical studies, ASPEN and WILLOW. Participants received 1 dose, once a day, of either BRINSUPRI 10 mg, BRINSUPRI 25 mg, or for the duration of the studies.

Both studies included people who:

Had non-cystic fibrosis

Had other conditions, including a history of asthma or COPD

Continued using their existing treatments

THE ASPEN STUDY

Participants: 1,721 people 12 years and older

Treatment period: 1 year (52 weeks)

BRINSUPRI 10 mg

583 people

BRINSUPRI 25 mg

575 people

Placebo

563 people

In the WILLOW study, 256 adults were treated once a day for 6 months, with 82 people receiving BRINSUPRI 10 mg, 87 people receiving BRINSUPRI 25 mg, and 87 people receiving placebo.

BRINSUPRI was proven to reduce bronchiectasis flares

BRINSUPRI reduced the risk of bronchiectasis (BE) flares graphic

BRINSUPRI reduced the risk of bronchiectasis (BE) flares chart

In the ASPEN study, BRINSUPRI reduced the risk of flares by 21.1% with the 10-mg dose and 19.4% with the 25-mg dose compared to those taking placebo when measured over 1 year.

A year without flares is possible with BRINSUPRI

When measured at 1 year in the ASPEN study, 48.5% of people taking BRINSUPRI 10 mg (283/583) or BRINSUPRI 25 mg (279/575) had no flares compared to 40.3% of people taking a placebo (227/563).

BRINSUPRI was proven to reduce lung function decline

Studies have shown that lung function naturally declines over time for everyone, but people with bronchiectasis experience greater decline. In the ASPEN study, BRINSUPRI 25 mg was shown to help reduce lung function decline when compared to placebo.

Reduction in lung function decline chart

Post-bronchodilator , a common test that determines how well your lungs are working, was measured at 1 year in the ASPEN study. People taking placebo saw a decline of 62 mL compared with 50 mL for those taking BRINSUPRI 10 mg. The difference in FEV₁ between the 10-mg dose and placebo was not significant.

People taking BRINSUPRI 25 mg saw a decline of 24 mL, which was a 61% reduction in lung function decline when compared to a 62-mL decline for those taking placebo.